Vladan V.
- Country
- Germany
- Department
- Hematology, Cell Therapy and Hemostaseology
Research Overview
- Dose-Escalation and Expansion Study of BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein Degrader, in Patients with B-Cell Malignancies
- Phase 1/2 Study of Subcutaneous Blinatumomab in Adults and Adolescents with Relapsed/Refractory or MRD+ B-cell Precursor Acute Lymphoblastic Leukemia
- AZD0120 Versus Standard Regimens in Relapsed or Refractory Multiple Myeloma: A Phase III Randomised Study
Data & Insights
Has run more than one trial at 194 of 386 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various blood cancers with particular emphasis on multiple myeloma, both newly diagnosed and relapsed/refractory cases. Their research includes novel therapeutic approaches using CAR T-cell therapy and innovative drug combinations.
- Multiple Myeloma Treatment Strategies
- Mantle Cell Lymphoma
- Non-Hodgkin Lymphomas
- Acute Myeloid Leukemia
Immunotherapy Applications
Focused on advancing immunotherapeutic approaches in cancer treatment, particularly through the development and implementation of cellular therapies. The investigator works with various forms of immunotherapy including monoclonal antibodies and targeted treatments.
- CAR T-cell Therapies
- Checkpoint Inhibition
- Antibody-based Treatments
- Combination Immunotherapy Strategies
Lymphoma Research
Expertise in treating various types of lymphomas, with particular focus on developing innovative treatment protocols for both classical and rare lymphoma variants. The research encompasses targeted therapies and personalized treatment approaches.
- Hodgkin Lymphoma
- Diffuse Large B-cell Lymphoma
- Primary Mediastinal B-cell Lymphoma
- Follicular Lymphoma
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.